## **PATENT COOPERATION TREATY**

# **PCT**

#### **INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220				
SI07P001WO	ACTION as well		as, where applicable, item 5 below.				
International application No.	International filing date (day/mor	th/year)	(Earliest) Priority Date (day/month/year)				
PCT/EP2004/053321	07/12/2004	07/12/2004 12/12/2003					
Applicant		<u>-</u>	-				
SIRENADE PHARMACEUTICALS A	AG						
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Se ansmitted to the International Bure	arching Auti au.	nority and is transmitted to the applicant				
This International Search Report consists	of a total ofs	heets.	•				
X It is also accompanied by	a copy of each prior art document	cited in this	report.				
Basis of the report     a. With regard to the language, the language in which it was filed, unline.	international search was carried o less otherwise indicated under this	ut on the basitem.	sis of the international application in the				
The international this Authority (Ru		s of a transl	ation of the international application furnished to				
b. X With regard to any nucleo	otide and/or amino acid sequenc	e disclosed	in the international application, see Box No. I.				
2. Certain claims were fou	nd unsearchable (See Box II).						
3. Unity of invention is lac	king (see Box III).						
4. With regard to the <b>title</b> ,							
X the text is approved as su	bmitted by the applicant.						
the text has been establis	hed by this Authority to read as fol	lows:					
1							
5. With regard to the abstract,							
X the text is approved as submitted by the applicant.							
			ty as it appears in Box No. IV. The applicant ch report, submit comments to this Authority.				
6. With regard to the drawings,							
a. the figure of the drawings to be p	published with the abstract is Figure	e No					
as suggested by	as suggested by the applicant.						
	s Authority, because the applicant	_	-				
	s Authority, because this figure be	tter characte	enzes the invention.				
b. X none of the figures is to b	e published with the abstract.		·				

International application No.

PCT/EP2004/053321

Вох	No. I	Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed nation, the international search was carried out on the basis of:
	a.	type of material  X a sequence listing table(s) related to the sequence listing
	b.	format of material  X in written format  X in computer readable form
	C.	contained in the international application as filed     filed together with the international application in computer readable form     furnished subsequently to this Authority for the purpose of search
2.	Х	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addi	tional comments:
1		

International Application No PCT/EP2004/053321

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/48 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE, CHEM ABS Data, MEDLINE

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
x _	US 2003/162222 A1 (MATHES RUTH ET AL) 28 August 2003 (2003-08-28) p.5, paragraph 0080	1-22
X ~	WO 00/42042 A (UNIV PRINCETON) 20 July 2000 (2000-07-20) page 83, line 23 - page 89, line 2	1-21
X V	VIOLETTE SHELIA M ET AL: "A Src SH2 selective binding compound inhibits osteoclast-mediated resorption" CHEMISTRY AND BIOLOGY (LONDON), vol. 7, no. 3, March 2000 (2000-03), pages 225-235, XP002280201 ISSN: 1074-5521 p.228, section "Effect of compoundstransformed cells" to end of this section on p. 229	1-21

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	<ul> <li>'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>'&amp;' document member of the same patent family</li> </ul>
Date of the actual completion of the international search  19 May 2005	Date of mailing of the international search report  06/06/2005
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Jacques, P

1

International Application No
PCT/EP2004/053321

•	ion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Helevant to claim No.
(	HANKE J H ET AL: "DISCOVERY OF A NOVEL, POTENT, AND SRC FAMILY-SELECTIVE TYROSINE KINASE INHIBITOR" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 2, 12 January 1996 (1996-01-12), pages 695-701, XP002051826 ISSN: 0021-9258 the whole document	22-27
X ν	NECKERS LEN: "Hsp90 inhibitors as novel cancer chemotherapeutic agents." TRENDS IN MOLECULAR MEDICINE. ENGLAND 2002, vol. 8, no. 4 Suppl, 2002, pages S55-S61, XP002280254 ISSN: 1471-4914 p.S58, left-hand column, two first lines. abstract	22-27
x	SAWYER T ET AL: "SRC INHIBITORS: GENOMICS TO THERAPEUTICS" EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 7, July 2001 (2001-07), pages 1327-1344, XP009003824 ISSN: 1354-3784 p. 1335, section 5.3 and p. 1338, section 6.figure 7	22-27
X	SUSVA M ET AL: "Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 12, 1 December 2000 (2000-12-01), pages 489-495, XP004226381 ISSN: 0165-6147 tables 1,2	22-27
A	YONEDA T ET AL: "HERBIMYCIN A, A PP60C-SRC TYROSINE KINASE INHIBITOR, INHIBITS OSTEOCLASTIC BONE RESORPTION IN VITRO AND HYPERCALCEMIA IN VIVO" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 91, June 1993 (1993-06), pages 2791-2795, XP000983736 ISSN: 0021-9738 the whole document	22-27

1

Information on patent family members

International Application No
PCT/EP2004/053321

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 2003162222	A1	28-08-2003	DE	10024174 A1	29-11-2001
			ΑT	288081 T	15-02-2005
			AU	6031401 A	26-11-2001
			CA	2409809 A1	15-11-2002
			DE	50105206 D1	03-03-2005
			WO	0188530 A2	22-11-2001
			EP	1282827 A2	12-02-2003
WO 0042042	Α	20-07-2000	AT	248170 T	15-09-2003
		•	AU	779008 B2	23-12-2004
			AU	2605300 A	01-08-2000
			CA	2369895 A1	20-07-2000
			DE	1140938 T1	09-01-2003
			DE	60004781 D1	02-10-2003
			DΕ	60004781 T2	08-07-2004
			DK	1140938 T3	22-12-2003
			EΡ	1140938 A2	10-10-2001
			EP	1321467 A2	25-06-2003
			ES	2206191 T3	16-05-2004
			JP	2002534524 T	15-10-2002
			WO	0042042 A2	20-07-2000
			US	2003073218 A1	17-04-2003
			US	6383790 B1	07-05-2002
			AU	6362000 A	13-02-2001
			CA	2380179 A1	01-02-2001
			EΡ	1196626 A2	17-04-2002
		•	JP	2003521890 T	22-07-2003
			WO	0107659 A2	01-02-2001
			US	6610483 B1	26-08-2003